- Raised $500k grant led by Israel Innovation Authority , May 2025
- Raised $500k grant led by Israel Innovation Authority , Jul 2024
- Raised $3.2M funding round, Apr 2022
About
IR-MED is developing a cutting-edge infrared spectroscopy and AI analysis technology platform as a basis for point-of-care decision support devices. The infrared spectroscopy technology allows harmless and non-invasive gathering of bio-information from patient blood and tissue. Bioinformation is then analyzed using the company’s AI process to provide healthcare professionals with decision support in the detection and monitoring of various disease conditions.
PressureSafe, the company’s first product based on this platform, is a handheld device designed to revolutionize early detection of pressure injuries (PI) affecting skin and underlying tissue. Pressure Injury in the US alone accounts for $26.8B in healthcare spending and results in 60,000 deaths annually. PressureSafe is expected to contribute to early detection of pressure injuries, regardless of patient skin tone. This will drive equitable healthcare and help reduce the toll and cost of PI.
IR-MED holds patents protecting its innovation in noninvasive tissue analysis and in modeling and analysis of subcutaneous tissue.
Funding history · 4 rounds · $8.7M total
Q&A
- What is IR-MED's primary focus?
- IR-MED specializes in developing noninvasive infrared-based diagnostics, utilizing infrared spectroscopy and AI analysis for point-of-care decision support devices.
- What is IR-MED's flagship product?
- IR-MED's first product is PressureSafe, a handheld device designed for the early detection of pressure injuries (PI) affecting skin and underlying tissue.
- When was IR-MED founded?
- IR-MED was founded in September 2012.
- What is IR-MED's total funding to date?
- IR-MED has raised a total of $8.73 million USD.
- Has IR-MED received any recent grants?
- Yes, IR-MED received a grant of $500,000 USD from the Israel Innovation Authority in July 2024, and another grant of $500,000 USD from the Israel Innovation Authority in May 2025.
- What is the current status of IR-MED?
- IR-MED is currently public on OTCQB, a status achieved in December 2020.
- Does IR-MED hold any patents?
- Yes, IR-MED holds patents protecting its innovation in noninvasive tissue analysis and in modeling and analysis of subcutaneous tissue.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | ir-medical.com |
|---|---|
| linkedin.com/company/70900354 |
Identifiers & details
| Founded | 2012-9 |
|---|---|
| Employees (exact) | 11 |
| Market cap | $2.9M |
| Status reason | Public on OTCQB on Dec, 2020; |
Radar intelligence
Patents
| EPO | 416 |
|---|
Web history (Wayback)
| Domain | ir-medical.com |
|---|